查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024618

再生醫學市場報告：按類型、應用、最終用戶和地區分類（2026-2034 年）

Regenerative Medicine Market Report by Type, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2025年全球再生醫學市場規模達318億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到1,433億美元，2026年至2034年的複合年成長率（CAGR）為17.65%。推動市場成長的因素包括：人們對移植排斥反應的日益關注、整形外科疾病再生醫學需求的成長、再生醫學在牙科領域的拓展以及再生醫學在創傷治療中應用的日益廣泛。

再生醫學市場的發展趨勢：

癌症治療產品需求增加

癌症治療產品需求的成長正在推動市場成長。癌症的特徵是細胞不受控制地增殖，常常導致組織損傷，而再生醫學可以有效解決這個問題。再生醫學能夠開發標靶治療，修復癌症或化療等治療副作用造成的組織損傷。例如，根據Money Control於2024年4月發表的報導，幹細胞療法（也稱為再生醫學）是一種利用幹細胞或其衍生物來促進病變、功能障礙或受損組織自然癒合反應的方法。幹細胞療法利用幹細胞來取代或修復受損組織，具有成為有效癌症治療方法的潛力。此外，大量研究和臨床試驗正在探索再生醫學在各種癌症治療中的應用潛力，這也推動了市場成長。再生醫學憑藉其革新癌症治療的潛力，正吸引大量研發投資。例如，2024年4月，德諾和諾德（de Novo）的DB107——一種針對高級別膠質母細胞瘤（HGG，包括膠質母細胞瘤（GBM））的生物標記指導的晚期基因療法——獲得了加州再生醫學研究所（CIRM）1180萬美元的資助，用於開展DB107在初診臨床階段的臨床成人腦腫瘤試驗中的一種臨床成人腦/II）。癌症發生率的上升以及對更有效、更人性化治療方法的追求，正在推動癌症治療領域對再生醫學的需求，顯著促進市場擴張。這些因素進一步推動了再生醫學市場的收入成長。

免疫療法的快速進展

免疫療法的快速發展正在推動市場成長。作為再生醫學的一個分支，免疫療法利用人體自身的免疫系統來對抗癌症和自體免疫疾病等。包括CAR-T細胞療法和免疫查核點抑制劑在內的免疫療法，透過增強人體識別和攻擊癌細胞的能力，徹底改變了癌症治療。例如，根據發表在《Pen Medicine》雜誌上的報導，CAR-T細胞療法是一種癌症免疫療法，它透過在實驗室中對稱為T細胞的免疫細胞進行基因改造，使其能夠更有效地識別和摧毀癌細胞。即使傳統治療方法無效，CAR-T療法對某些類型的癌症也具有很高的療效。此外，與化療和放射線治療等傳統治療方法相比，CAR-T療法通常嚴重較少，從而改善了患者的預後。另外，根據發表在WebMD網站上的報導，免疫療法副作用較少的原因在於它針對的是免疫系統而非細胞本身。此外，目前正在進行大規模的臨床試驗和研究項目，旨在最佳化免疫療法，從而推動該領域的創新。例如，2024年2月，Imnon宣佈在紀念斯隆-凱特琳癌症中心啟動針對進行性卵巢癌患者的基於DNA的白細胞介素-12（IL-12）免疫療法I/II期臨床試驗“IMNN-001”。該試驗預計將納入50名III/IV期癌症患者。這些因素正在推動再生醫學市場佔有率的擴大。

該產品在整形外科和美容醫學領域有著廣泛的應用。

美容外科和美學領域產品的廣泛應用是推動該市場成長的主要動力。再生醫學，包括脂肪幹細胞療法，被用於乳房重建和臉部回春等手術中的自然組織增容。例如，於默奧大學發表的一篇論文指出，移植脂肪組織來源的幹細胞可以在乳癌再生新的乳房，而無需矽膠植入或大規模手術。此外，再生醫學技術也被用於最大限度地減少手術、事故或損傷造成的疤痕，並改善美容效果。基於幹細胞的再生醫學也被用於毛髮再生，以解決脫髮和頭髮稀疏的問題。例如，2024年3月，Bosley和HAIRCLUB的母公司Aderans與Stemson Therapeutics達成協議，授予Stemson獨家權利，基於Aderans的取得專利的毛髮再生細胞療法技術，研發和銷售毛髮再生治療產品。此次合作將為Stemson公司提供互補技術。 Stemson是一家利用誘導性多功能幹細胞細胞（iPS細胞）開發細胞療法以阻止脫髮進展的公司。 Stemson不僅將為脫髮患者提供多種解決方案，還將接管Aderans公司正在進行的二期臨床試驗細胞療法毛髮再生項目，並將其技術整合到Aderans公司現有的脫髮治療細胞療法開發平臺中。這些因素正在推動再生醫學的發展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球再生醫學市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 幹細胞療法
  • 生物材料
  • 組織工程
  • 其他

第7章 市場區隔：依應用領域分類

  • 骨移植替代物
  • 骨骼和關節疾病
  • 皮膚科
  • 心血管系統
  • 中樞神經系統
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 專科診所
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • bluebird bio, Inc.
    • CRISPR Therapeutics
    • Gamida Cell Inc
    • Gilead Sciences, Inc.
    • IOVANCE Biotherapeutics, Inc.
    • Mesoblast Ltd
    • Novartis AG
    • Orchard Therapeutics plc
    • SanBio Co, Ltd.
    • Vertex Pharmaceuticals
Product Code: SR112026A2517

The global regenerative medicine market size reached USD 31.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 143.3 Billion by 2034, exhibiting a growth rate (CAGR) of 17.65% during 2026-2034. The increasing transplant rejection concerns, the rising demand for regenerative therapies for orthopedic conditions, the growing dental regeneration, and the escalating medicine use in wound healing are some of the factors propelling the market growth.

REGENERATIVE MEDICINE MARKET ANALYSIS:

  • Major Market Drivers: The rising prevalence of chronic diseases such as diabetes, heart disease, and osteoarthritis owing to the aging population along with the growing research in stem cell therapies and genetic engineering drives innovation in regenerative medicine. Moreover, the escalating use of stem cells and other cell-based therapies for tissue regeneration and repair is also catalyzing the market.
  • Key Market Trends: The increasing awareness among patients about regenerative treatment options along with the funding and regulatory support for regenerative medicine research and development is expected to boost the market demand. In addition to this, the advancements in biotechnology enable more precise and effective regenerative therapies, bolstering the market growth.
  • Competitive Landscape: Some of the leading regenerative medicine market companies are bluebird bio, Inc., CRISPR Therapeutics, Gamida Cell Inc, Gilead Sciences, Inc., IOVANCE Biotherapeutics, Inc., Mesoblast Ltd, Novartis AG, Orchard Therapeutics plc, SanBio Co, Ltd., and Vertex Pharmaceuticals, among many others.
  • Geographical Landscape: According to the report, North America accounted for the largest market share. Government agencies in the region have shown support for regenerative medicine research through funding initiatives, grants, and regulatory pathways designed to accelerate the development and commercialization of innovative therapies.
  • Challenges and Opportunities: Regulatory hurdles in the approval of regenerative medicines along with the high cost of research, development, and clinical trials in regenerative medicines are hampering the market growth. However, advances in regenerative medicine, including cell therapy and gene editing technologies, enable personalized treatment approaches tailored to individual patient characteristics and disease profiles, further escalating the market demand.

REGENERATIVE MEDICINE MARKET TRENDS:

Increasing Product Demand in Cancer Treatment

The increasing product demand in cancer treatment is catalyzing the market growth. Cancer, characterized by uncontrolled cell growth, often leads to tissue damage, which can be addressed through regenerative therapies. Regenerative medicine allows for the development of targeted therapies that can repair damaged tissues caused by cancer or side effects of treatments like chemotherapy. For instance, according to an article published by Money Control in April 2024, stem cell therapy, also known as regenerative medicine, is a method of promoting the natural healing response of sick, malfunctioning, or wounded tissues by employing stem cells or their derivatives. Stem cell therapy uses stem cells to replace or repair damaged tissues, which has the potential to be an effective cancer treatment. Moreover, robust research and clinical trials explore the potential of regenerative therapies in various cancer types, fostering the market growth. The potential for regenerative therapies to revolutionize cancer treatment attracts investment in research and development. For instance, in April 2024, Denovo's DB107, a biomarker-guided late-stage gene therapy for high-grade glioma (HGG) including glioblastoma (GBM), received US$ 11.8 Million funding from the California Institute for Regenerative Medicine (CIRM) in order to perform a Phase 1/2 clinical trial of DB107 in patients with newly diagnosed HGG, a type of adult brain cancer. The rising prevalence of cancer and the pursuit of more effective, patient-friendly treatments fuel the demand for regenerative medicine in cancer care, contributing significantly to the market's expansion. These factors are further bolstering the regenerative medicine market revenue.

Rapid Advancements in Immunotherapy

Rapid advancements in immunotherapy are propelling the market. Immunotherapy, a subset of regenerative medicine, harnesses the body's immune system to fight diseases, including cancer and autoimmune disorders. Immunotherapies like CAR-T cell therapy and immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the body's ability to recognize and combat cancer cells. For instance, according to an article published by Pen Medicine, CAR T cell therapy is a form of cancer immunotherapy treatment in which immune cells called T cells are genetically changed in a lab to help them locate and destroy cancer cells more efficiently. CAR T treatment can be extremely effective against certain forms of cancer, even when conventional treatments fail. They often have fewer severe side effects than traditional treatments like chemotherapy and radiation therapy, improving patient outcomes. Moreover, according to an article published by Web MD, immunotherapy has fewer side effects as it targets the immune system rather than the cells in the body. Moreover, robust clinical trials and research initiatives focus on optimizing immunotherapies, driving innovation in the field. For instance, in February 2024, Imunon announced the commencement of patient enrollment in IMNN-001, a Phase I/II clinical trial for DNA-based interleukin-12 (IL-12) immunotherapy in patients with advanced ovarian cancer at Memorial Sloan Kettering Cancer Center. The study intended to include fifty patients with Stage III/IV cancer. These factors are contributing to the regenerative medicine market share.

Widespread Product Applications in Cosmetic Surgery and Aesthetics

The widespread product applications in cosmetic surgery and aesthetics are a driving force behind the growth of this market. Regenerative therapies, including adipose-derived stem cell treatments, are used for natural tissue augmentation in procedures like breast reconstruction and facial rejuvenation. For instance, according to an article published by Umea University, adipose tissue stem cell transplantation makes it possible to regenerate a new breast without the need for silicone implants or extensive surgery following the removal of breast cancer. Moreover, regenerative techniques are employed to minimize the appearance of scars resulting from surgeries, accidents, or injuries, enhancing aesthetic outcomes. Stem cell-based regenerative therapies are utilized for hair restoration, addressing hair loss and baldness concerns. For instance, in March 2024, Aderans Company, the parent company of Bosley and HAIRCLUB, and Stemson Therapeutics signed an agreement to grant Stemson the sole right to conduct research, develop, and market hair regeneration therapeutic products based on Aderans' patented hair regeneration cell therapy technology. Through this collaboration, Stemson, a cell therapy developer in induced pluripotent stem cells (iPSC) for reversing hair loss, obtained a complementary technology. In addition to providing a variety of solutions for individuals suffering from hair loss, Stemson would take up Aderans' Phase 2 clinical-stage cell therapy hair regeneration program and incorporate the technology into its current hair loss cell therapy development pipeline. These factors are driving the adoption of regenerative medicine.

REGENERATIVE MEDICINE INDUSTRY SEGMENTATION:

Breakup by Type:

  • Stem Cell Therapy
  • Biomaterial
  • Tissue Engineering
  • Others

Stem cell therapy dominates the market

According to the regenerative medicine market outlook, stem cell therapy harnesses the unique regenerative properties of stem cells to repair and replace damaged or dysfunctional tissues and organs. It offers diverse therapeutic applications, including orthopedics, cardiology, neurology, and oncology. This versatility attracts investment and research, expanding its market presence. Clinical trials and case studies demonstrate the effectiveness of stem cell therapies in treating previously incurable conditions, boosting patient and physician confidence. With the global population aging, there's an increasing prevalence of age-related diseases and degenerative conditions, driving the demand for regenerative treatments. Furthermore, the regulatory bodies recognize stem cell therapies' potential, resulting in streamlined approvals and guidelines, further encouraging the market growth. Patients seeking alternatives to conventional treatments are turning to stem cell therapies for better outcomes and reduced side effects. The potential of stem cell therapies attracts investments, fostering research and development and expanding accessibility. Advances in stem cell isolation, culturing, and delivery methods improve treatment efficacy, enhancing their applications. Stem cell therapy providers are expanding their reach globally, making these treatments available to a wider patient population. For instance, in October 2022, Century Therapeutics and Bristol Myers Squibb revealed a research collaboration and license agreement to develop and market up to four induced pluripotent stem cell-derived, modified natural killer cell and/or T cell projects for hematologic malignancies and solid tumors.

Breakup by Application:

  • Bone Graft Substitutes
  • Osteoarticular Diseases
  • Dermatology
  • Cardiovascular
  • Central Nervous System
  • Others

Dermatology dominates the market

According to the regenerative medicine industry analysis, dermatology is a vital application within regenerative medicine, focusing on the restoration and regeneration of skin tissues. It addresses a wide spectrum of dermatological concerns, ranging from scar reduction and wound healing to treating skin disorders and aging-related skin conditions. Regenerative approaches in dermatology include using stem cells, growth factors, and tissue engineering techniques, offering patients innovative and minimally invasive solutions for achieving healthier, more youthful, and blemish-free skin. This segment is gaining traction due to the growing demand for cosmetic and aesthetic enhancements and the need for effective treatments for various skin ailments, ultimately contributing to the overall growth of the regenerative medicine market. For instance, in September 2023, Dr. Samuel Lynch, a biotechnology entrepreneur, launched Lynch Regenerative Medicine, Inc. (LRM), a new advanced biotherapeutics skincare firm that would address unmet clinical requirements in both the cosmetic and advanced wound care industry.

Breakup by End User:

  • Hospitals
  • Specialty Clinics
  • Others

Hospitals dominate the market

As per the regenerative medicine industry insights, hospitals serve as prominent end users within the regenerative medicine market, playing a pivotal role in the adoption and growth of regenerative therapies. They serve as hubs for advanced medical care and are integral for several reasons. Hospitals provide the infrastructure and expertise necessary for conducting complex regenerative procedures, such as organ transplants and stem cell therapies, ensuring patient safety and optimal outcomes. They also facilitate clinical trials and research initiatives, allowing for the development and testing of innovative regenerative treatments. Furthermore, hospitals are key in delivering regenerative therapies to patients, especially for acute injuries, chronic diseases, or conditions requiring specialized medical attention. As healthcare institutions embrace regenerative medicine, hospitals remain central in its expansion, offering cutting-edge treatments to a diverse patient population.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the regenerative medicine industry statistics, North America represents a significant region in the regenerative medicine market, driving growth through several key factors. The region's advanced healthcare infrastructure, robust research and development capabilities, and high healthcare expenditure contribute to the adoption of regenerative therapies. It is home to numerous renowned research institutions, biotechnology companies, and academic centers specializing in regenerative medicine, fostering innovation and clinical advancements. Regulatory support and well-defined approval processes in countries like the United States accelerate the introduction of regenerative treatments to the market. A growing aging population with age-related conditions also fuels the demand for regenerative solutions. Moreover, a strong focus on addressing chronic diseases, sports injuries, and aesthetic concerns further propels the use of regenerative therapies in North America. These factors collectively position North America as a prominent growth driver in the regenerative medicine sector. For instance, in October 2023, Bayer AG inaugurated its first Cell Therapy launch facility in Berkeley, California, in order to offer regenerative medicines to patients.

COMPETITIVE LANDSCAPE:

Top companies are strengthening the market through innovation, strategic partnerships, and extensive research. They invest heavily in research and development, pushing the boundaries of regenerative medicine, uncovering new therapies, and expanding treatment options. They conduct large-scale clinical trials to demonstrate the safety and efficacy of regenerative therapies, gaining regulatory approvals and boosting market confidence. Top companies develop a diverse portfolio of regenerative products, catering to various medical conditions and applications, from orthopedics to oncology. These companies expand globally, ensuring wider access to their therapies and increasing market reach. Partnerships with research institutions, healthcare providers, and pharmaceutical companies facilitate knowledge sharing and the development of novel therapies. They navigate complex regulatory landscapes, ensuring their therapies meet stringent safety and quality standards instilling trust in healthcare professionals and patients. Top companies engage in patient advocacy and education, raising awareness about the benefits of regenerative medicine, thus driving demand. Their track record of success attracts investments, enabling further research and development of groundbreaking therapies.

The report has provided a comprehensive analysis of the competitive landscape in the regenerative medicine market. Detailed profiles of all major companies have also been provided.

  • bluebird bio, Inc.
  • CRISPR Therapeutics
  • Gamida Cell Inc
  • Gilead Sciences, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Mesoblast Ltd
  • Novartis AG
  • Orchard Therapeutics plc
  • SanBio Co, Ltd.
  • Vertex Pharmaceuticals

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Regenerative Medicine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Stem Cell Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Biomaterial
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Tissue Engineering
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Bone Graft Substitutes
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Osteoarticular Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dermatology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Central Nervous System
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 bluebird bio, Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 CRISPR Therapeutics
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Gamida Cell Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Gilead Sciences, Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 IOVANCE Biotherapeutics, Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Mesoblast Ltd
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Orchard Therapeutics plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SanBio Co, Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Vertex Pharmaceuticals
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Regenerative Medicine Market: Major Drivers and Challenges
  • Figure 2: Global: Regenerative Medicine Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Regenerative Medicine Market: Breakup by Type (in %), 2025
  • Figure 4: Global: Regenerative Medicine Market: Breakup by Application (in %), 2025
  • Figure 5: Global: Regenerative Medicine Market: Breakup by End User (in %), 2025
  • Figure 6: Global: Regenerative Medicine Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Regenerative Medicine Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Regenerative Medicine (Stem Cell Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Regenerative Medicine (Stem Cell Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Regenerative Medicine (Biomaterial) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Regenerative Medicine (Biomaterial) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Regenerative Medicine (Tissue Engineering) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Regenerative Medicine (Tissue Engineering) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Regenerative Medicine (Other Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Regenerative Medicine (Other Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Regenerative Medicine (Bone Graft Substitutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Regenerative Medicine (Bone Graft Substitutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Regenerative Medicine (Osteoarticular Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Regenerative Medicine (Osteoarticular Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Regenerative Medicine (Dermatology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Regenerative Medicine (Dermatology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Regenerative Medicine (Cardiovascular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Regenerative Medicine (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Regenerative Medicine (Central Nervous System) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Regenerative Medicine (Central Nervous System) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Regenerative Medicine (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Regenerative Medicine (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Regenerative Medicine (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Regenerative Medicine (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Regenerative Medicine (Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Regenerative Medicine (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Regenerative Medicine (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Regenerative Medicine (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: North America: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: North America: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: United States: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: United States: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Canada: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Canada: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia Pacific: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia Pacific: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: China: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: China: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Japan: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Japan: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: India: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: India: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: South Korea: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: South Korea: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Australia: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Australia: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Indonesia: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Indonesia: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Others: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Others: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Europe: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Europe: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Germany: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Germany: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: France: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: France: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United Kingdom: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United Kingdom: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Italy: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Italy: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Spain: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Spain: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Russia: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Russia: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Latin America: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Latin America: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Brazil: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Brazil: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Mexico: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Mexico: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Middle East and Africa: Regenerative Medicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Middle East and Africa: Regenerative Medicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Global: Regenerative Medicine Industry: SWOT Analysis
  • Figure 83: Global: Regenerative Medicine Industry: Value Chain Analysis
  • Figure 84: Global: Regenerative Medicine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Regenerative Medicine Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Regenerative Medicine Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Regenerative Medicine Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Regenerative Medicine Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Regenerative Medicine Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Regenerative Medicine Market Structure
  • Table 7: Global: Regenerative Medicine Market: Key Players